ProCE Banner Activity

RELATIVITY-047: Biomarker Analysis of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma

Conference Coverage

Exploratory biomarker analysis of patients with previously untreated advanced melanoma in RELATIVITY-047 suggests that expansion of selected immune cell populations is more prominent with nivolumab + relatlimab vs nivolumab alone and that lower pretreatment CD8+ T-cell levels in tumors may be associated with increased benefit from nivolumab + relatlimab vs nivolumab alone.

Released: October 25, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc